Abstract

Review Article

Stages in COVID-19 vaccine development: The Nemesis, the Hubris and the Elpis

Vinod Nikhra*

Published: 22 December, 2020 | Volume 4 - Issue 1 | Pages: 126-135

The nemesis: SARS-CoV-2 pandemic: Leaving in its wake millions of infections, accompanied by an immense magnitude of morbidity and multitude of mortality, and an unfathomable economic toll, the COVID-19 pandemic has led to a global calamity. An effective and safe COVID-19 vaccine is urgently needed to prevent the disease, thwart the complications and avert deaths resulting from unrestrained transmission of the infection.

The hubris: Vaccine development: While most of the platforms of vaccine candidates have focused on the spike (S) protein and its variants as the primary antigen of COVID-19 infection, various techniques involved include nucleic acid technologies (RNA and DNA), non-replicating viral vectors, peptides, recombinant proteins, live attenuated and inactivated viruses. There are novel vaccine technologies being developed using next-generation strategies for precision and flexibility for antigen manipulation relating to SARS-CoV-2 infection mechanisms.

The elpis: Updates and prospects: There were nine different technology platforms under research and development to create an effective vaccine against COVID 19. Although there are no licensed vaccines against COVID-19 yet, there are various potential vaccine candidates under development and advanced clinical trials. Out of them, one having undergone phase III clinical trials, has become available in some countries for use among the high-risk groups following emergency use authorization. Other COVID-19 vaccines may soon follow the suit.

Conclusion: Hopes and concerns: The hope of benefiting from the vaccine to the extent that it may be the only way to tide over and control the COVID-19 pandemic, is accompanied by the likely fear of adverse effects and opposition in public for COVID-19 vaccination, including the vaccine hesitancy. Further, there is concern among scientific circles that vaccine may have opposite of the desired effect by causing antibody-dependent disease enhancement.

Read Full Article HTML DOI: 10.29328/journal.ijcv.1001028 Cite this Article Read Full Article PDF

Keywords:

COVID-19 vaccines; Genomic sequencing; Coronavac; Covaxin; EpiVacCorona; Moderna’s vaccine; Oxford-AstraZeneca COVID-19 vaccine; Pfizer-BioNTech COVID-19 vaccine; Sputnik V; Vaccine technology platforms; Vaccine hesitancy

References

  1. Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, et al. An mRNA Vaccine against SARS-CoV-2 — Preliminary Report. N Engl J Med. 2020; 383: 1920-1931. PubMed: https://pubmed.ncbi.nlm.nih.gov/32663912/
  2. Heaton PM. Editorial - The Covid-19 Vaccine-Development Multiverse. N Engl J Med. 2020; 383: 1986-1988. PubMed: https://pubmed.ncbi.nlm.nih.gov/32663910/
  3. World Health Organization, Geneva. Draft landscape of COVID-19 vaccine candidates. 2020. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
  4. Corbett KS, Flynn B, Foulds KE, Francica JR, Boyoglu-Barnum S, et al. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. N Engl J Med. 2020; 383; 1544-1555. PubMed: https://pubmed.ncbi.nlm.nih.gov/32722908/
  5. DeFrancesco L. COVID-19 antibodies on trial. Nat Biotechnol. 2020; 38: 1242–1252. PubMed: https://pubmed.ncbi.nlm.nih.gov/33087898/
  6. Zheng J. SARS-CoV-2: An Emerging Coronavirus that Causes a Global Threat. Int J Biol Sci. 2020; 16: 10; 1678-1685. PubMed: https://pubmed.ncbi.nlm.nih.gov/32226285/
  7. Whole genome of novel coronavirus, 2019-nCoV, sequenced. 2020. https://www.sciencedaily.com/releases/2020/01/200131114748.htm; https://thepetridish.my/2020/02/21/genome-of-coronavirus-sequenced-by-pasteur-institute/
  8. The Vaccine Quest. Scientific American. 2020; 322: 40-43.
  9. Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, et al. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell. 2020; 182: 812–827. PubMed: https://pubmed.ncbi.nlm.nih.gov/32697968/
  10. Plante JA, Liu Y, Liu J, Xia H, Johnson BA, et al. Spike mutation D614G alters SARS-CoV-2 fitness and neutralization susceptibility. Nature. 2020. PubMed:
  11. McAuley AJ, Kuiper MJ, Durr PA, Bruce MP, Barr J, et al. Experimental and in silico evidence suggests vaccines are unlikely to be affected by D614G mutation in SARS-CoV-2 spike protein. NPJ Vaccines. 2020; 5: 96. PubMed: https://pubmed.ncbi.nlm.nih.gov/33083031/
  12. Naqvi AAT, Fatima K, Mohammad T, Fatima U, Singh IK, et al. Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2020; 10: 165878. PubMed: https://pubmed.ncbi.nlm.nih.gov/32544429/
  13. Meredith LW, Hamilton WL, Warne B, Houldcroft CJ, Hosmillo M, et al. Rapid implementation of SARS-CoV-2 sequencing to investigate cases of healthcare associated COVID-19: a prospective genomic surveillance study. Lancet Infect Dis. 2020; 20: 1263-1272. PubMed: https://pubmed.ncbi.nlm.nih.gov/32679081/
  14. Ng KW, Faulkner N, Cornish GH, Rosa A, Harvey R, et al. Pre-existing and de novo humoral immunity to SARS-CoV-2 in humans. Science. 2020; 370: 1339-1343. PubMed: https://pubmed.ncbi.nlm.nih.gov/33159009/
  15. Liu C, Zhou Q, Li Y, Garner LV, Watkins SP, et al. Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases. ACS Cent Sci. 2020; 6: 315–331. PubMed: https://pubmed.ncbi.nlm.nih.gov/32226821/
  16. Yu J, Tostanoski LH, Peter L, Mercado NB, McMahan K, et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science. 2020; 369: 806-811. PubMed: https://pubmed.ncbi.nlm.nih.gov/32434945/
  17. Huang J, Huang H, Wang D, Wang C, Wang Y. Immunological strategies against spike protein: Neutralizing antibodies and vaccine development for COVID‐19. Clinical and Translational Medicine. 2020; 10: e184. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7586990/
  18. Liu H, Wu NC, Yuan M, Bangaru S, Torres JL, et al. Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity. Immunity. 2020; 53: 1272-1280.e5. PubMed: https://pubmed.ncbi.nlm.nih.gov/33242394/
  19. Yuan M, Wu NC, Zhu X, Chang-Chun DL, So RTY, et al. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science. 2020; 368: 630-633. PubMed: https://pubmed.ncbi.nlm.nih.gov/32245784/
  20. Juno JA, Tan HX, Lee WS, Reynaldi A, Kelly HG, et al. Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. Nat Med. 2020; 26: 1428–1434. PubMed: https://pubmed.ncbi.nlm.nih.gov/32661393/
  21. Jeyanathan M, Afkhami S, Smaill F, Miller MS, Lichty BD, et al. Immunological considerations for COVID-19 vaccine strategies. Nat Rev Immunol. 2020; 20: 615–632. PubMed: https://pubmed.ncbi.nlm.nih.gov/32887954/
  22. Le TT, Cramer JP, Chen R, Mayhew S. Evolution of the COVID-19 vaccine development landscape. Nature Reviews Drug Discovery. 2020; 19: 667–668. PubMed: https://pubmed.ncbi.nlm.nih.gov/32887942/
  23. Chauhan G, Madou MJ, Kalra S, Chopra V, Ghosh D, et al. Nanotechnology for COVID-19: Therapeutics and Vaccine Research. ACS Nano. 2020; 14: 7760-7782. PubMed: https://pubmed.ncbi.nlm.nih.gov/32571007/
  24. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines
  25. https://www.who.int/news/item/06-11-2020-who-icmra-joint-statement-on-the-need-for-improved-global-regulatory-alignment-on-covid-19-medicines-and-vaccines
  26. Bull S, Jamrozik E, Binik A, Parker MJ. SARS-CoV-2 challenge studies: ethics and risk minimisation. J Med Ethics. 2020; 106504. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7520819/
  27. McNeil S. Overview of Vaccine Efficacy and Vaccine Effectiveness. Canadian Center for Vaccinology. 2020. https://www.who.int/influenza_vaccines_plan/resources/Session4_VEfficacy_VEffectiveness.PDF
  28. Peter Thielen of Johns Hopkins Applied Physics Laboratory in conversation with Hamilton Jon. ‘How Mutations in The Coronavirus May Affect Development Of A Vaccine’. 2020. https://www.npr.org/2020/06/25/883557549/how-mutations-in-the-coronavirus-may-affect-development-of-the-vaccine
  29. Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, et al. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med. 2020; 383; 1920-19231. PubMed: https://pubmed.ncbi.nlm.nih.gov/32663912/
  30. Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomized, controlled, phase 2/3 trial. Lancet. 2020; 396: 1979-1993. PubMed: https://pubmed.ncbi.nlm.nih.gov/33220855/
  31. Tim Locke. Are UK Doctors Sceptical of COVID-19 Vaccine? 2020. https://www.medscape.com/viewarticle/941492.
  32. Neumann-Böhme S, Varghese NE, Sabat I, et al. Once we have it, will we use it? A European survey on willingness to be vaccinated against COVID-19. European J Health Econom. 2020; 21: 977–982.
  33. Source: HCHE/ Uni Hamburg 2020 survey in Den, Fr, Netherland, PT, IT, UK, DNK. 2020. https://www.hche.uni-hamburg.de/en/forschung/corona.html
  34. Yamey G, Schäferhoff M, Hatchett R, Pate M, Zhao F, et al. Ensuring global access to COVID 19 vaccines. Lancet. 2020; 395: 1405–1406. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271264/
  35. Cohen J. China's vaccine gambit. Science. 2020; 370: 1263-1267. PubMed: https://pubmed.ncbi.nlm.nih.gov/33303601/
  36. Halabi S, Heinrich A, Omer SB. No-Fault Compensation for Vaccine Injury - The Other Side of Equitable Access to Covid-19 Vaccines. N Engl J Med. 2020; 383: e125. PubMed: https://pubmed.ncbi.nlm.nih.gov/33113309/
  37. Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for greater than six months after infection. Preprint at bioRxiv. 2020.
  38. Wang J, Zand MS. The potential for antibody-dependent enhancement of SARS-CoV-2 infection: Translational implications for vaccine development. J Clin Transl Sci. 2020; 1-4. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7274027/
  39. Diamond MS, Pierson TC. The challenges of vaccine development against a new virus during a pandemic. Cell Host and Microbe. 2020; 27: 699–703. PubMed: https://pubmed.ncbi.nlm.nih.gov/32407708/
  40. Lazarus JV, Ratzan SC, Palayew A, Gostin LO, Larson HJ, et al. A global survey of potential acceptance of a COVID-19 vaccine. Nat Med. 2020; 1-4. PubMed: https://pubmed.ncbi.nlm.nih.gov/33082575/
  41. Reiter PL, Pennell ML, Katz ML. Acceptability of a COVID-19 vaccine among adults in the United States: How many people would get vaccinated? Vaccine. 2020; 38: 6500-6507. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7440153/
  42. Bell S, Clarke R, Mounier-Jacka S, Walker JL, Paterson P. Parents’ and guardians’ views on the acceptability of a future COVID-19 vaccine: A multi-methods study in England. Vaccine. 2020; 38: 7789-7798. PubMed: https://pubmed.ncbi.nlm.nih.gov/33109389/

Figures:

Figure 1

Figure 1

Figure 1

Figure 2

Figure 1

Figure 3

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?